Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Corey A. Siegel, Adam S. Cheifetz et al.|Clinical Gastroenterology and Hepatology|2019Cited by 336
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled TrialsJennifer Jones, Corey A. Siegel, Shane Devlin et al.|Clinical Gastroenterology and Hepatology|2015Cited by 121
The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit AllGil Melmed, Corey A. Siegel, Brennan Spiegel et al.|Clinical Gastroenterology and Hepatology|2010Cited by 50
Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Melmed, Corey A. Siegel, Peter M. Irving et al.|Clinical Gastroenterology and Hepatology|2016Cited by 48
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel DiseaseShane Devlin, Corey A. Siegel, Gil Melmed et al.|Inflammatory Bowel Diseases|2016Cited by 30